FAQ on Clene Inc.'s Regulatory Advances for CNM-Au8 in ALS and MS Treatment
Summary
Clene Inc. has made significant progress in its regulatory strategy for CNM-Au8, with FDA meetings scheduled to discuss its ALS and MS programs, aiming for accelerated approval pathways based on biomarker and survival data analyses.
What is Clene Inc. working on?
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS, Parkinson’s disease, and multiple sclerosis, with its investigational therapy CNM-Au8®.
What recent regulatory developments has Clene Inc. announced?
Clene Inc. announced feedback from a Type C meeting with the FDA on its statistical analysis plan for ALS, resubmitted a revised SAP, and scheduled two additional FDA meetings in Q3 2025 for ALS and MS programs.
Why is the FDA feedback important for Clene Inc.?
The FDA feedback is crucial as it guides Clene Inc. in refining its statistical analysis plan for CNM-Au8®, supporting a potential NDA submission under the accelerated approval pathway for ALS treatment.
When does Clene Inc. anticipate FDA acceptance of its revised SAP?
Clene Inc. anticipates FDA acceptance of its revised statistical analysis plan this summer, with NfL analyses scheduled for early Q4 2025.
What are the upcoming FDA meetings about?
The upcoming FDA meetings include assessing long-term ALS survival data for accelerated approval consideration and reviewing Phase 2 MS trial results to discuss a Phase 3 study targeting cognitive improvement.
Where can I find more information about Clene Inc.?
More information about Clene Inc. can be found on their website at www.Clene.com and in their newsroom at https://ibn.fm/CLNN.
What is CNM-Au8®?
CNM-Au8® is an investigational first-in-class therapy by Clene Inc. that aims to improve central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress.
How does Clene Inc. plan to use NfL biomarker data?
Clene Inc. plans to use neurofilament light (NfL) biomarker data from its Expanded Access Protocol for ALS to support a potential NDA submission under the accelerated approval pathway, with analyses scheduled for early Q4 2025.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 99523